Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer.
Journal
Prostate cancer and prostatic diseases
ISSN: 1476-5608
Titre abrégé: Prostate Cancer Prostatic Dis
Pays: England
ID NLM: 9815755
Informations de publication
Date de publication:
22 Feb 2024
22 Feb 2024
Historique:
received:
01
02
2024
accepted:
13
02
2024
revised:
06
02
2024
medline:
23
2
2024
pubmed:
23
2
2024
entrez:
22
2
2024
Statut:
aheadofprint
Résumé
Combined androgen deprivation therapy (ADT) and radiotherapy (RT) improves outcomes for intermediate and high-risk prostate cancer. Treatment intensification with abiraterone acetate/prednisone (AAP) provides additional benefit for high-risk disease. We previously reported 3-year outcomes of a single-arm prospective multicenter trial (AbiRT trial) of 33 patients with unfavorable intermediate risk (UIR) and favorable high risk (FHR) prostate cancer undergoing short course, combination therapy with ADT, AAP, and RT. Here we report the final analysis demonstrating a high rate of testosterone recovery (97%) and excellent biochemical progression-free survival (97%) at 5 years. These data support comparative prospective studies of shorter, more potent ADT courses in favorable high-risk prostate cancer.
Identifiants
pubmed: 38388778
doi: 10.1038/s41391-024-00811-5
pii: 10.1038/s41391-024-00811-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : W81XWH-09-1-0152
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : W81XWH-14-2-0198
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PMP, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34:1748–56.
doi: 10.1200/JCO.2015.64.8055
pubmed: 26976418
Krauss DJ, Karrison T, Martinez AA, Morton G, Yan D, Bruner DW, et al. Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial. J Clin Oncol. 2023. https://doi.org/10.1200/JCO.22.02390 .
Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, et al. Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology RTOG 9202. Int J Radiat Oncol Biol Phys. 2017;98:296–303.
doi: 10.1016/j.ijrobp.2017.02.004
pubmed: 28463149
pmcid: 5603177
Nabid A, Carrier N, Martin A-G, Bahary J-P, Lemaire C, Vass S, et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized phase III trial. Eur Urol. 2018;74:432–41.
doi: 10.1016/j.eururo.2018.06.018
pubmed: 29980331
Nabid A, Carrier N, Martin A-G, Vigneault E, Vincent F, Brassard M-A, et al. Testosterone recovery in patients with prostate cancer treated with radiotherapy and different ADT duration: long-term data from two randomized trials. J Clin Oncol. 2023;41:300.
doi: 10.1200/JCO.2023.41.6_suppl.300
Koontz BF, Hoffman KE, Halabi S, Healy P, Anand M, George DJ, et al. Combination of radiation therapy and short-term androgen blockade with abiraterone acetate plus prednisone for men with high- and intermediate-risk localized prostate cancer. Int J Radiat Oncol Biol Phys. 2021;109:1271–8.
doi: 10.1016/j.ijrobp.2020.11.059
pubmed: 33259932
Bolla M, De Reijke TM, Van Tienhoven G, Van Den Bergh ACM, Oddens J, Poortmans PMP, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516–27.
doi: 10.1056/NEJMoa0810095
pubmed: 19516032
Armstrong AJ, Liu VY, Selvaraju RR, Chen E, Simko J, DeVries S, et al. Development and validation of an AI-derived digital pathology-based biomarker to predict benefit of long-term androgen deprivation therapy with radiotherapy in men with localized high-risk prostate cancer across multiple phase III NRG/RTOG trials. J Clin Oncol. 2023;41:5001.
doi: 10.1200/JCO.2023.41.16_suppl.5001
Nguyen PL, Kollmeier M, Rathkopf DE, Hoffman KE, Zurita AJ, Spratt DE, et al. FORMULA-509: a multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP). J Clin Oncol. 2023;41:303.
doi: 10.1200/JCO.2023.41.6_suppl.303